Completion of subscription of convertible loans
21 Marzo 2024 - 4:32PM
UK Regulatory
Completion of subscription of convertible loans
|
|
|
|
|
|
|
|
Completion of subscription of convertible loans |
|
|
March 21, 2024
Company Announcement no. 08
On 7 February 2024, the Board of Directors of Pharma Equity Group
decided to issue convertible loans in accordance with the
authorisation in the Company's Articles of Association under
Article 4.3.A. The convertible loans have now been fully
subscribed and the remaining amount of DKK 500,000 out of the total
amount of DKK 7,100,000, announced in Company Announcement no. 4 of
7 February 2024, has now been paid to the Company.
With reference to company announcements no. 01 of 22 January 2024,
no. 03 of 25 January 2024 and no. 04 of 7 February 2024, as of the
date of this company announcement, a total of DKK 16,014,795 has
been subscribed and paid to the company, and the total capital
increase due to conversion of already subscribed convertible loans
amounts to DKK 23,055,497.
For further information, please contact:
|
|
|
Thomas Kaas
Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114
Christian Vinding Thomsen, Chairman of the Board of Directors of
Pharma Equity Group A/S, phone: +45 2622 7222 |
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing
extensive support, resources, and expertise to drive the
development and success of these projects. As a strategic partner,
Pharma Equity Group works closely with Reponex Pharmaceuticals,
prioritizing the advancement of innovative medical solutions and
breakthrough therapies. Every effort is currently directed towards
ensuring the utmost success and impact of Reponex Pharmaceuticals'
medical projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open to new
strategic investments for continuous growth.
- 2024 03 21 - Announcement no. 08 - UK - Convertible Loans
Grafico Azioni Pharma Equity Group A/s (LSE:0REU)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Pharma Equity Group A/s (LSE:0REU)
Storico
Da Gen 2024 a Gen 2025
